Cargando…

非小细胞肺癌EGFR-TKI治疗临床获益后颅内转移机制研究进展

Currently epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is widely used for treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, intracranial metastasis and progression could happen to some patients while their primary tumors in lung stabilize...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000228/
https://www.ncbi.nlm.nih.gov/pubmed/26302350
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.08.09
Descripción
Sumario:Currently epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is widely used for treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, intracranial metastasis and progression could happen to some patients while their primary tumors in lung stabilize or even shrink after EGFR-TKI treatment. And mechanisms on this phenomenon remain unclear. Recently, increasing studies have demonstrated that it is associated with the pharmacokinetics of EGFR-TKI, heterogeneity between primary tumors and metastases, EGFR mutation status and prolonged survival. Therefore, we write this review to discuss the mechanisms on intracranial metastasis of NSCLC after clinical benefit from EGFR-TKI.